Fact Source: Financial Supervisory Service DART / 2025-01-14
Disclosure Type: Execution of Single Sales/Supply Contract
💡 3-Second Summary
SAMSUNG BIOLOGICS has executed a monumental contract manufacturing organization (CMO) agreement worth approximately KRW 2.07T (USD 1.41B) with a Europe-based pharmaceutical firm, representing a staggering 56.15% of its total annual revenue from the 2023 fiscal year.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals (Other Sales/Supply Contract)
- Contract Amount: KRW 2,074,694,843,000 (Confirmed amount: USD 1,410,110,000)
- Applied Exchange Rate: Fixed at the initial base rate of USD/KRW 1,471.30 as of January 14, 2025.
- Ratio to Recent Revenue: 56.15% (Recent annual revenue based on 2023 consolidated financial statements: KRW 3,694,588,767,068)
- Counterparty: A pharmaceutical company located in Europe (Identity withheld until December 31, 2030, due to operational confidentiality).
- Contract Period: From December 13, 2024 (Commencement Date) to December 31, 2030 (Approximately 6 years).
- Key Terms: No down payment or advance payment is provided (None).
- Historical Timeline Context: This contract represents the finalized formal agreement following the preliminary disclosure titled “Major Management Matters Related to Investment Judgment” filed on December 19, 2024.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This supply contract marks one of the largest single transactions in SAMSUNG BIOLOGICS’ corporate history, serving as a defining fundamental indicator that verifies the firm’s global manufacturing dominance and portfolio execution capacity. Securing a reliable backlog equivalent to over 56% of the 2023 financial year’s top-line revenue through a single transaction substantially elevates long-term earnings visibility.
From an analytical standpoint, international macro investors should prioritize foreign exchange structures and revenue recognition timelines. Because the contract is locked in USD (approx. USD 1.41B), executing the transaction during a favorable USD/KRW macro threshold of 1,471.30 significantly expands the initial KRW-converted translation metrics. Final realized yields may fluctuate depending on currency dynamics over the life cycle. Furthermore, given the six-year duration, this multi-billion dollar backlog will be recognized progressively based on manufacturing milestone completions and facility allocation schedules rather than in an immediate quarterly surge.
The filing does not provide qualitative metrics regarding specific product types or exact profit margin structures due to strict confidentiality parameters. However, anchoring a mega-scale operational backlog with a major European client directly expands the company’s global validation record, acting as a major stabilizing variable for long-term institutional asset allocations.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has kicked off the fiscal pipeline by logging an absolute mega-deal in the European theater. Accumulating an order book worth 56% of a legacy annual revenue floor in a single booking underscores the sheer scale of the company’s available capacity and manufacturing dependability. Locking in a USD-denominated contract when the macro conversion rate rests above 1,470 provides management with a strategic FX buffer for upcoming translated metrics.
While the counterparty remains unmapped under standard confidentiality clauses until 2030, the multi-billion dollar scale implies an arrangement with a premier tier-one global player. Institutional analysts should look past near-term quarterly expectations, as this backlog is engineered for progressive conversion across a six-year window. The primary value driver is the long-term optimization of facility utilization rates, which effectively ensures high asset efficiency and supports structural cash flow durability over the decade.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
